Bisphosphonates Can Prevent Skeletal Complications of Malignant Bone Disease from Prostate Cancer and Renal Cell Carcinoma  Fred Saad  European Urology Supplements  Volume 6, Issue 11, Pages 683-688 (June 2007) DOI: 10.1016/j.eursup.2007.03.006 Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 1 Zoledronic acid consistently reduced all types of skeletal-related events (SREs) at 2 yr in patients with hormone-refractory prostate cancer. HCM: hypercalcemia of malignancy. Adapted from Saad F et al [10,17]. European Urology Supplements 2007 6, 683-688DOI: (10.1016/j.eursup.2007.03.006) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 2 Kaplan-Meier estimates of time to first skeletal complication for patients treated with 4mg zoledronic acid (ZOL) compared with placebo at 2 yr. SRE: skeletal-related event. Adapted from Saad F et al [10] and with permission from Coleman RE. Oncologist 2004;9(suppl 4):14–27. © AlphaMed Press [18]. European Urology Supplements 2007 6, 683-688DOI: (10.1016/j.eursup.2007.03.006) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 3 Zoledronic acid increases time to first skeletal-related event (SRE) in patients with renal cell carcinoma. NR: not reached. Adapted with permission from Lipton A et al [25]. European Urology Supplements 2007 6, 683-688DOI: (10.1016/j.eursup.2007.03.006) Copyright © 2007 European Association of Urology Terms and Conditions